Most Recent
J&J-owned Janssen Pharmaceutica has sued Juno Pharmaceuticals, alleging the Australian off-patent drug maker is threatening to infringe its patent for a schizophrenia drug by seeking to list its own products on the PBS.
Pharmaceutical giant Johnson & Johnson has denied knowingly selling alleged ineffective medications under its Benadryl, Sudafed and Codral brands, saying research indicated the phenylephrine-containing products worked.
Johnson & Johnson has slammed a class action over allegedly ineffective cold and flu medications, telling a judge it has "real concerns" with how the case has been framed.
Healthcare giant Johnson & Johnson is facing a new class action alleging it sold talcum powder that was contaminated with asbestos and caused reproductive system cancers in women.
Women who were allegedly injured by defective pelvic mesh implants can apply to set aside two approved settlements against Johnson & Johnson and Boston Scientific worth $405 million.
Johnson & Johnson has been hit with a class action for allegedly pushing ineffective cold and flu medications containing phenylephrine onto customers for decades.
A judge has signed off on a bill that brings the total settlement administration costs in a class action against Johnson & Johnson unit De Puy to over $13 million, amid a push by some judges to open the settlement administration gig up to competition.
As Johnson & Johnson loses its second attempt to use bankruptcy protection to resolve tens of thousands of US cases over its talcum powder products, a law firm has launched a class action investigation on behalf of Australian women who regularly used the powder and were later diagnosed with cancer.
A former top judge appointed to decide the first-ever contest to administer a class action settlement has set out his criteria for making the choice, and has warned that giving the firm running a case a monopoly right to dole out the proceeds could lead to higher costs for group members and poorer settlement outcomes.
Shine Lawyers’ bid to recoup "exorbitant" interest on a loan it took out to run pelvic mesh class actions against Johnson & Johnson has raised new ethical dilemmas beyond the usual "sweaty palms and huge vexation" in most group proceedings, a judge has said.